AI’s Impact on the Drug Targeting Process - with Ramesh Durvasula of Lilly
Today’s guest is Ramesh Durvasula, Senior Vice President of R&D IT at Lilly. Ramesh joins us on the program today to discuss AI’s impact on the drug targeting process, particularly in helping pharmaceutical leaders like Lilly better predict what potential drugs to invest in for bringing to market and when. With increased certainty in drug targeting, Ramesh explains how AI capabilities are driving clinical trials to be used as an alternative form of healthcare. Visit emerj.com/beg1 to learn more about the practical steps for AI deployment for non-technical professionals.